TEST:

StrataMRD™ test

P=N/A; N=100000 --> 295 | Trial completion date: Dec 2036 --> Feb 2024 | Enrolling by invitation --> Terminated | Trial primary completion date: Dec 2035 --> Oct 2023; Sentinel MRD test offers no additional or increased benefits to patients compared to current marketed alternatives

Personalized cfDNA based MRD testing had high sensitivity and specificity vs. routine imaging for detecting disease recurrence in patients with GU cancers. Combined tumor testing with validated angiogenesis inhibitor and immunotherapy treatment selection biomarkers enables individualized adjuvant therapy decision making.

"Strata Oncology, Inc...announced that Lehigh Valley Topper Cancer Institute and the University of Michigan Health Rogel Cancer Center have joined as clinical trial sites in the Strata SentinelTM trial, a prospective, observational study of the StrataMRD^TM minimal residual disease test that has the potential to shift the paradigm of cancer care, bringing the use of biomarker-matched precision therapies to earlier stages of the disease."

"Strata Oncology, Inc...announced enrollment of the first patient in the Strata Sentinel trial, a prospective, observational study that will evaluate the ability of the investigational StrataMRD test to detect cancer recurrence in advance of standard of care techniques across solid tumors, as well as the clinical benefit of treatment in early-stage patients who are or become ctDNA-positive after surgery or other therapy with curative intent."